- Home
- LPAA vs ACRS Comparison
LPAA vs ACRS Comparison
Compare LPAA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | ACRS |
|---|---|---|
| Founded | 2024 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.3M | 311.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | LPAA | ACRS |
|---|---|---|
| Price | $10.73 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 2.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | $31.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.21 | $1.09 |
| 52 Week High | $10.74 | $4.89 |
Technical Indicators
Market Signals| Indicator | LPAA | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 58.94 |
| Support Level | $10.40 | $3.16 |
| Resistance Level | $10.74 | $4.22 |
| Average True Range (ATR) | 0.01 | 0.27 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 88.89 | 81.86 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.